Press release

Basel, Switzerland, May 19, 2015

Karger launches Kidney Diseases, a new review journal for research exchange between East and West

Karger Publishers has announced the launch of *Kidney Diseases*, a new journal that aims to provide a platform for Asian and Western research to further and support communication and exchange of knowledge. The journal will be officially launched at the ERA-EDTA Congress in London, May 28–31, 2015.

The new journal *Kidney Diseases* publishes invited review articles which cover the most recent clinical and basic science relevant to the entire field of nephrological disorders, including glomerular diseases, acute and chronic kidney injury, tubulointerstitial disease, hypertension and metabolism-related disorders, end-stage renal disease, and genetic kidney disease. The journal will contain special articles prepared by two opinion leaders – one from the East and one from the West – that compare genetics, epidemiology, diagnostic methods and treatment options of a particular disease. Each issue of *Kidney Diseases* will be devoted to a special topic. In the first issue, IgA nephropathy, which has a higher prevalence in Asia, and diabetic nephropathy, the leading cause of end-stage renal disease in most Western countries, have been chosen as the main topics.

The launch of the journal stems from the recognition that the medical community benefits from enhanced mutual recognition of particularities from the different regions of the world. Exchange of knowledge and shared experiences improve global understanding and foster progress.

Zhi-Hong Liu, Director of the National Clinical Research Center for Kidney Diseases at Jinling Hospital, Nanjing University School of Medicine, China, and the former President of the Chinese Society of Nephrology, serves as Editor-in-Chief of *Kidney Diseases*. According to Liu: ‘There is much ethnic, socioeconomic, environmental, healthcare resource and developmental heterogeneity between countries. These diversities have a major effect on the incidence, prevalence and pattern of kidney diseases between the East and West. Unfortunately, basic and clinical research on kidney diseases has lagged behind that of other medical fields. In particular, the number of randomized controlled trials is lower than that in other medical subspecialties. There is a great need for additional research on kidney diseases. Undoubtedly, the concept of *Kidney Diseases* will establish a new and unique landmark in research publications.’

Consulting Editor Giuseppe Remuzzi, former President (2013 – March 2015) of the International Society of Nephrology (ISN) and creator of the ISN initiative called ‘0 by 25’ feels that ‘Nobody should die of preventable and treatable acute kidney injury (AKI) by 2025. The hope is that the ISN will contribute during the next decade to ensure that we can lessen the high burden in terms of death following untreated AKI in the poorest parts of the world by 2025. There are now increasing opportunities to promote new nephrology partnerships by joining efforts between West and East in more technologically advanced clinical and laboratory research to address the many unsolved problems around kidney disease.’

The journal will be officially launched at the ERA-EDTA Congress in London, May 28–31, 2015. For more information please visit Karger Publishers at this meeting at booth D185.

The first issue has been published and is available at [www.karger.com/kdd](http://www.karger.com/kdd).

**Editor-in-Chief: Zhi-Hong Liu**, Director of the National Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, China. She is a member of the Chinese Academy of Engineering, former President of the Chinese Society of Nephrology, and Councilor of the International Society of Nephrology. Her primary fields of research are glomerulonephritis and renal replacement therapy. She was honored with the National Science and Technology Progress Award of China.
Consulting Editor: Giuseppe Remuzzi is Professor of Nephrology on a ‘chiara fama’ basis (as of June 2015) and Director of the Department of Medicine at the Papa Giovanni XXIII Hospital, Bergamo, Italy. He also directs the Negri Bergamo Laboratories of the ‘Mario Negri’ Institute for Pharmacological Research and the affiliated Clinical Center for Rare Diseases ‘Aldo e Cele Dacc’, in Bergamo. Particularly far-reaching are his contributions to our understanding of the pathophysiology of hemolytic uremic syndrome and the role of protein trafficking in renal disease progression. He also contributed to the definition of novel therapeutic interventions to delay the progression of proteinuric nephropathies and autosomal dominant polycystic kidney disease. He has authored and co-authored more than 1,275 scientific articles, reviews and monographs.

Karger Publishers
Karger Publishers in Basel, Switzerland, is a globally active medical and scientific publishing company. Independent and family-run in the fourth generation, Karger is dedicated to serving the information needs of the scientific community with publications of high-quality content, covering all fields of medical science.

For further information: Website Karger Publishers: www.karger.com
Website Kidney Diseases: www.karger.com/kdd